Anavex Life Sciences : Corporate Presentation from JPM 2023

J.P. Morgan Healthcare Conference Presentation

January 12, 2023

Forward Looking Statements

This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex® Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause act ual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in reports filed by Anavex Life Sciences Corp. with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Anavex Life Sciences Corp. undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Anavex Life Sciences Corp. cannot be sure when or if it will be permitted by regulatory agencies to undertake clinical trials or to commence any particular phase of any clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Anavex Life Sciences Corp. will obtain regulatory approval for any "phase" of clinical trials. We also cannot be sure of the clinica l outcome for efficacy or safety of our compounds. Potential investors should refer to the risk factors in our reports filed on Edgar.

2

Anavex Overview

NASDAQ	HEADQUARTERS
AVXL	NYC
TEAMMATES	CASH & CASH EQUIVALENTS1
37	$149.2M
CNS DISORDERS	PATIENTS WITH CNS
MARKET OPPORTUNITY2	DISORDERS WORLDWIDE3
$232.2B	67.5M+

World-wide patent protection for all listed product candidates

Anavex is dedicated to therapeutic discovery and development of novel small molecule treatments for central nervous system (CNS) diseases including Alzheimer's Disease, Parkinson's Disease Dementia and Rett Syndrome, among other rare diseases

Company's precision platform, SIGMACEPTOR™, has enabled the development of drugs that unlock the body's own defenses to treat, and

in some cases potentially reverse, CNS conditions

Aiming to bring the Company's treatments to market to benefit patients across the globe

Our Values

Precision

Therapeutics

Every person is unique: aspire to develop therapeutic treatments tailored to suit each individual's unique medical condition

Community-based Insights

Value and rely on community- based partnerships to inform our decision making and strategy development processes

Scientific

Innovation

Therapeutic development model is designed to identify and innovate novel therapeutic solutions that are rooted

in science

Inclusion &

Equitable Access

Global institutional need for change: committed to serving the diverse human population and to implementing inclusive and equitably accessible therapeutic programs

1. As of September 30, 2022.
2. Source:https://www.alliedmarketresearch.com/central-nervous-disorders-therapeutics-market-A13121

3

3. Sources available on slide 20 of this presentation.

Well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities

Precision medicine platform and novel central nervous system mechanism improve chance of clinical success

4

Anavex Precision Platform Enables a Novel Approach

Targeting CNS conditions with genomic precision and restoring neuronal homeostasis via SIGMAR1 activation

Proprietary SIGMACEPTOR™ Discovery Platform produces small molecule therapeutic candidates for targeting the SIGMAR1 mRNA biomarker

Age-related Changes	Progressive CNS	ANAVEX®2-73
		Pathology (e.g., AD, PD)
Chronic CNS pathologies,	Impaired body-own	ANAVEX®2-73 (blarcamesine)
including progressive chronic	compensatory SIGMAR1	re-establishes the body's own
Alzheimer's, cause exhaustion	response to chronic	SIGMAR1 response and
of the body's own SIGMAR1	cellular stress	restores SIGMAR1 levels
activators, impairing the
body's response to
chronic cellular stress

Beneficial therapeutic effect for patients

5